Chemical Compound
Physostigmine salicylate
CAS Registry Number
57-64-7
Primary Record
Physostigmine salicylate
- In stock
- 5,456 g
- Purity
- 98.2 %
- CAS
- 57-64-7
Compound Identifiers & Properties
- CAS
- 57-64-7
- PubChem CID
- 657348
- SMILES
- C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C.C1=CC=C(C(=C1)C(=O)O)O
- Canonical SMILES
- CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C.O=C(O)c1ccccc1O
Names & Synonyms
- Physostigmine salicylate
- Antilirium
- Eserine salicylate
- Isopto Eserine
- 57-64-7
- Physostol salicylate
- Physostigmine (salicylate)
- Physostigmine monosalicylate
- Antilirium (TN)
- Isopto P-ES
- Physostigmini salicylas
- ANTICHOLIUM
- AC1LCWEA
- Eserine salicylate salt
- Spectrum_000223
- Opera_ID_194
- RefChem:56715
- 2046ZRO9VU
- 57-64-7 (salicylate)
- UNII-2046ZRO9VU
- PHYSOSTIGMINESALICYLATE
- (-)-Physostigmine salicylate
- RCRA waste no. P188
- MLS000028388
- CCRIS 3405
- Physostigmine salicylate [JAN]
- Physostigmine salicylate CRS
- Physostigmine salicylate salt
- SCHEMBL41555
- KBioSS_000703
- CHEBI:48883
- physostigmine; salicyclic acid
- DivK1c_000339
- NSC-757275
- SPECTRUM1500486
- DTXSID80883232
- Physostigmine, salicylate (1:1)
- HZOTZTANVBDFOF-PBCQUBLHSA-N
- Physostigmine salicylate(1:1)
- AR-44
- C22H27N3O5
- CHEMBL338975
- orb1310908
- SCHEMBL29787035
- C15H21N3O2.C7H6O3
- EINECS 200-343-8
- ERK5-2A03
- HMS501A21
- HY-B1266R
- KBio1_000339
- KBio2_000703
- KBio2_003271
- KBio2_005839
- Physostigmine salicylate [USP:JAN]
- MFCD00135659
- NINDS_000339
- DTXCID501022781
- HMS1920H12
- HMS2091P16
- HMS2235G19
- Pharmakon1600-01500486
- BCP25378
- CID 5992
- HY-B1266
- TL-1380
- Physostigmine salicylate (JAN/USP)
- 6290AF
- CCG-39918
- CID657348
- EBC-75102
- EX-A11396
- NSC757275
- PHYSOSTIGMINE SALICYLATE [MI]
- Physostigmine salicylate [USAN:JAN]
- SMR000058606
- AKOS037515711
- Physostigmine (salicylate) (Standard)
- CID:657348
- NSC 757275
- SDCCGMLS-0002925.P003
- IDI1_000339
- PHYSOSTIGMINE SALICYLATE [MART.]
- PHYSOSTIGMINE SALICYLATE [VANDF]
- NCGC00024464-02
- PHYSOSTIGMINE SALICYLATE [USP-RS]
- PHYSOSTIGMINE SALICYLATE [WHO-DD]
- PHYSOSTIGMINE SALICYLATE [WHO-IP]
- AC-37462
- DA-56832
- Eserine salicylate salt, >=97.0% (N)
- MS-27151
- SID:134221904
- 57-64-7, 57-47-6 [physostigmine]
- C15-H21-N3-O2.C7-H6-O3
- CS-0013051
- FT-0699661
- NS00078948
- Salicylic acid, compd. with physostigmine (1:1)
- PHYSOSTIGMINI SALICYLAS [WHO-IP LATIN]
- D02418
- PHYSOSTIGMINE SALICYLATE [EP MONOGRAPH]
- PHYSOSTIGMINE SALICYLATE [USP MONOGRAPH]
- A903540
- C026718
- SR-01000075341
- SR-01000075341-3
- SR-01000075341-5
- SR-01000075341-7
- Q27121383
- Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate)
- B0084-028331
- Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl methylcarbamate (1:1)
- (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate 2-hydroxybenzoate
- [(3Ar,8bS)-3,4,8b-trimethyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]indole-3,4-diium-7-yl] N-methylcarbamate;2-oxidobenzoate
- Physostigmine salicylate, European Pharmacopoeia (EP) Reference Standard
- Physostigmine salicylate, United States Pharmacopeia (USP) Reference Standard
- (3aS,8aR)-1,3a,8-trimethyl-5-(methylcarbamoyloxy)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indolium salicylate
- [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate (2-hydroxybenzoic acid) salt
- [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate, 2-hydroxybenzoic acid
- [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate; 2-hydroxybenzoic acid
- [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate;2-hydroxybenzoic acid
- 2-Hydroxybenzoic acid--(3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate (1/1)
- 200-343-8
- Benzoic acid, 2-hydroxy-, compd with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate ester (1:1)
- Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl N-methylcarbamate (1:1)
- Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)
- Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl methylcarbamate ester (1:1)
- Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate ester (1:1)
- Benzoic acid, 2-hydroxy-, compound with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)
- Physostigmine salicylate; (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate salicylate; Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1) (9CI); Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1); Physostigmine salicylate (6CI); Physostigmine, monosalicylate (8CI); Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, mono(2-hydroxybenzoate) (salt) (9CI); Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate) (salt); Salicylic acid, compd. with physostigmine (1:1) (8CI); (-)-Physostigmine salicylate; Eserine salicylate; Isopto Eserine